Wolverine Asset Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Wolverine Asset Management’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-251,104	Closed	-$2.54M	–	2364
2022 Q4	$2.54M	Hold	251,104	–	–	0.03%	512
2022 Q3	$2.49M	Hold	251,104	–	–	0.03%	501
2022 Q2	$2.48M	Buy	251,104 +85,170	+51%	+$835K	0.02%	495
2022 Q1	$1.64M	Buy	165,934 +281	+0.2%	+$2.77K	0.02%	574
2021 Q4	$1.63M	Sell	165,653 -10,954	-6%	-$108K	0.02%	618
2021 Q3	$1.72M	Sell	176,607 -9,168	-5%	-$88.9K	0.01%	541
2021 Q2	$1.8M	Buy	185,775 +184,102	+11,004%	+$1.79M	0.01%	460
2021 Q1	$16K	Buy	+1,673	New	+$16.2K	﹤0.01%	1797

Wolverine Asset Management's BIOT Position: Q1 2023 in Review

Wolverine Asset Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 251,104 shares — an estimated $2.54M sold.

Wolverine Asset Management first reported a position in BIOT in Q1 2021 and held it in 8 quarters. The position peaked at $2.54M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Wolverine Asset Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Wolverine Asset Management sold 251,104 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $2.54M.
Wolverine Asset Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 8 quarters.
Wolverine Asset Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $2.54M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Wolverine Asset Management's 13F filing for Q1 2023, filed 8 May 2023.